![]() | F Estelle R SimonsUniversity of Manitoba | Department of Pediatrics Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada | Department ... |
KOL Resume for F Estelle R Simons
Year | |
---|---|
2020 | University of Manitoba |
2019 | Department of Pediatrics Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada |
2018 | Department of Pediatrics and Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Winnipeg, Canada |
2017 | Department of Pediatrics and Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB Canada |
2016 | Section of Allergy and Clinical Immunology, Department of Pediatrics & Child Health, University of Manitoba, Winnipeg, MB, Canada. Department of Pediatrics and Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada |
2015 | University of Manitoba, Medicine, Winnipeg, MB Canada |
2014 | University of Manitoba Department of Pediatrics & Child Health Winnipeg MB Canada |
2013 | Department of Pediatrics & Child Health and Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada |
2012 | Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada University of Manitoba, Winnipeg, MB, CANADA |
2011 | Department of Pediatrics & Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada |
2010 | Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada |
2009 | Department of Immunology and the CIHR National Training Program in Allergy and Asthma, University of Manitoba, Winnipeg, Man., Canada |
2008 | University of Manitoba, Manitoba, Canada CIHR National Training Program in Allergy and Asthma Research, Departments of Immunology Department of Pediatrics and Child Health |
2007 | Department of Pediatrics and Child Health, University of Manitoba |
F Estelle R Simons: Influence Statistics
Concept | World rank |
---|---|
anaphylaxis background | #1 |
children 15 30 | #1 |
ragweed vaccine | #1 |
wheal 192 hours | #1 |
suppression h1antagonist | #1 |
similarities allergic rhinitis | #1 |
bones eye allergic | #1 |
salbutamol 30 minutes | #1 |
025 1 24 | #1 |
2specific immunoglobulin | #1 |
wt or10 | #1 |
ace inhibitors epinephrine | #1 |
cetirizine applied | #1 |
newer h1receptor antagonists | #1 |
oldgeneration h1antihistamines | #1 |
new 67 | #1 |
epinephrine 03 | #1 |
natural reimmunization | #1 |
epi intramuscular injections | #1 |
injector children | #1 |
desensitization mosquito | #1 |
fev1 postexercise | #1 |
treatment allergic disorders | #1 |
timely epinephrine injection | #1 |
auto injectors | #1 |
cmax epinephrine | #1 |
urticaria pediatric population | #1 |
ccl22 peanuttolerant individuals | #1 |
epinephrine autoinjectors treatment | #1 |
virusdependent expression | #1 |
allergic disorders terms | #1 |
treatment beclomethasone | #1 |
epinephrine evidence | #1 |
09 nacl cmax | #1 |
h1receptor occupancy | #1 |
clinical risk anaphylaxis | #1 |
autoinjectors systematic review | #1 |
18‐month study | #1 |
prescriptions inhaled | #1 |
neutrophils allergic asthmatics | #1 |
variances diphenhydramine loratadine | #1 |
auviq | #1 |
potential aid treatment | #1 |
anaphylaxis pathogenesis | #1 |
chlorpheniramine ingestion | #1 |
hydroxyzine elimination patients | #1 |
levels mosquito | #1 |
levocetirizine urticaria | #1 |
natural desensitization | #1 |
eppcs epinephrine | #1 |
Open the FULL List in Excel | |
Prominent publications by F Estelle R Simons
BACKGROUND: Platelet-activating factor (PAF) is an important mediator of anaphylaxis in animals, and interventions that block PAF prevent fatal anaphylaxis. The roles of PAF and PAF acetylhydrolase, the enzyme that inactivates PAF, in anaphylaxis in humans have not been reported.
METHODS: We measured serum PAF levels and PAF acetylhydrolase activity in 41 patients with anaphylaxis and in 23 control patients. Serum PAF acetylhydrolase activity was also measured in 9 patients with peanut ...
Known for Paf Acetylhydrolase | Patients Anaphylaxis | Activating Factor | Peanut Hypersensitivity | Grade 1 |
BACKGROUND: An inhaled glucocorticoid is currently the medication of choice for long-term control of persistent asthma in children. The role of long-acting beta2-adrenergic-receptor agonists, such as salmeterol, needs to be defined.
METHODS: We conducted a randomized, double-blind, placebo-controlled, parallel-group, one-year study of 241 children (mean [+/-SD] age, 9.3+/-2.4 years) with clinically stable asthma and less than one month of prior glucocorticoid use. We compared inhaled ...
Known for Salmeterol Placebo | Children Asthma | Airway Hyperresponsiveness | Inhaled Glucocorticoid | 12 Months |
We compared the protective effect and duration of action of inhaled formoterol, a new, long-acting, selective beta 2-agonist, to inhaled salbutamol and placebo in a double-blind, randomized, crossover study in 16 children with asthma with a mean age of 10.3 +/- 0.4 years. Mean baseline FEV1 was 96 +/- 3% predicted and mean provocative concentration of methacholine (milligrams per milliliter) required to decrease FEV1 by 20% (PC20) was 0.81 +/- 0.25 mg/ml of methacholine. On the 4 study ...
Known for 12 Hours | Fev1 Pc20 | Inhaled Formoterol | New Long | Topic Doseresponse Relationship |
BACKGROUND: Peanut allergy is one of the most common forms of food allergy encountered in clinical practice. In most cases, it does not spontaneously resolve; furthermore, it is frequently implicated in acute life-threatening reactions. The current management of peanut allergy centres on meticulous avoidance of peanuts and peanut-containing foods. Allergen-specific oral immunotherapy (OIT) for peanut allergy aims to induce desensitisation and then tolerance to peanut, and has the ...
Known for Peanut Allergy | Oit Treatment | Preschool Desensitization | Specific Oral | Arachis Child Child |
The balance of interleukin-4 (IL-4) to interferon-gamma (IFN-gamma) production that is induced following exposure to common environmental antigens is believed to be instrumental in determining whether hypersensitivity or clinical unresponsiveness results to that antigen. To date, evaluation of cytokine (protein) production has been based predominantly on allergen-reactive CD4 T-cell clones or activation of fresh unselected peripheral blood mononuclear cell (PBMC) populations with ...
Known for Allergic Rhinitis | Gamma Production | Normal Controls | Il4 Ifn | Primary Culture |
BACKGROUND: The evidence base for the use of H1-antihistamines in the treatment of perennial allergic rhinitis is considerably smaller than it is in the treatment of seasonal allergic rhinitis.
OBJECTIVE: We hypothesized that desloratadine, a new, nonsedating selective H1-antihistamine, would be efficacious and safe in the treatment of perennial allergic rhinitis.
METHODS: In a multicenter, randomized, placebo-controlled, double-blind, parallel-group study, 676 patients with symptomatic ...
Known for Perennial Allergic | Desloratadine Treatment | 4 Weeks | Rhinitis Symptoms | Morning Evening |
The Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology was charged with formulating a position paper regarding the potential release of intranasal corticosteroids for over-the-counter use. We took the position that safety issues regarding this proposal would be our sole concern. We reviewed the literature to evaluate the frequency and severity of potential adverse events related to the administration of ...
Known for Intranasal Corticosteroids | Joint Task Force | Allergy Asthma | Perennial Rhinitis | Inhalation Administration |
Cetirizine: A pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis
[ PUBLICATION ]
In a double-blind, randomized, parallel-group 5-week study, cetirizine, 5 mg or 10 mg daily, was ingested by 10 and nine children, respectively. Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427.6 +/- SD, 144.2 ng/ml, 1.4 +/- 1.1 hours after the 5 mg dose, and 978.4 +/- 340.6 ng/ml, 0.8 +/- 0.4 hours after the 10 mg dose. The dose-independent serum-elimination half-life of cetirizine was 7.1 +/- 1.6 hours after cetirizine, 5 mg, and 6.9 +/- 1.6 hours after ...
Known for Allergic Rhinitis | Dose Cetirizine | 5 10 | 24 Hours | Wheal Flare |
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Report of the NIAID-Sponsored Expert Panel
[ PUBLICATION ]
Food allergy is an important public health problem that affects children and adults and may be increasing in prevalence. Despite the risk of severe allergic reactions and even death, there is no current treatment for food allergy: the disease can only be managed by allergen avoidance or treatment of symptoms. The diagnosis and management of food allergy also may vary from one clinical practice setting to another. Finally, because patients frequently confuse nonallergic food reactions, ...
Known for Food Allergy | Diagnosis Management | Clinical Guidelines | Infectious Diseases | National Institute |
BACKGROUND: Auvi-Q is a novel epinephrine autoinjector (EAI) that provides audio and visual cues for patients at risk for life-threatening allergic reactions.
OBJECTIVE: We tested the preference for Auvi-Q or EpiPen with regard to method of instruction, preference to carry, device size, and device shape.
METHODS: This large, multicenter, simulated-use study evaluated whether adults (aged 18-65 years), caregivers (parents/guardians aged 18-65 years of children aged 5-17 years), and ...
Known for Epipen Auviq | Preference Auvi | Epinephrine Autoinjector | Aged Anaphylaxis | 1865 Years |
OBJECTIVES: The long-acting beta2-adrenergic agonist salmeterol prevents exercise-induced asthma, but tolerance may develop to its bronchoprotective effect. We wanted to ascertain if the development of tolerance could be prevented by using a low-dose treatment regimen of 50 microg once daily, instead of the usual dose of 50 microg twice daily, in adolescents receiving regular glucocorticoid inhalations. Methods. In a randomized, double-blind, 2x28-day crossover study, we administered ...
Known for Induced Asthma | Bronchoprotective Salmeterol | 50 Microg | Inhaled Glucocorticoid | Drug Tolerance |
Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis
[ PUBLICATION ]
BACKGROUND: This is the first prospective, randomized, double-blind, placebo-controlled study showing statistical improvement of an H(1)-antihistamine in children with seasonal allergic rhinitis in all symptoms throughout the entire treatment period.
OBJECTIVE: This randomized, placebo-controlled, parallel-group, double-blind study was performed to assess the efficacy and safety of fexofenadine in children with seasonal allergic rhinitis.
METHODS: This study was conducted at 148 centers ...
Known for Seasonal Allergic Rhinitis | Fexofenadine Children | Nasal Congestion | Aged 6 | Efficacy Safety |
BACKGROUND: Anaphylaxis is a serious hypersensitivity reaction that is rapid in onset and may cause death. Adrenaline is recommended as the initial treatment of choice for anaphylaxis.
OBJECTIVES: To assess the benefits and harms of adrenaline (epinephrine) in the treatment of anaphylaxis.
SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 1), MEDLINE (1966 to March 2007), EMBASE (1966 to March 2007), CINAHL (1982 ...
Known for Adrenaline Anaphylaxis | Epinephrine Treatment | Adrenergic Agonists Inclusion | Ongoing Trials | Unpublished Material |
BACKGROUND: Identification of patients at risk for asthma exacerbations can assist physicians in addressing disease management and improve asthma-related health outcomes.
OBJECTIVE: We sought to evaluate whether level of impairment, as defined by the 2007 asthma guidelines, predicts risk for future asthma exacerbations.
METHODS: The study included children aged 6 to 11 years (n = 82) and adolescent/adult patients aged 12 years and older (n = 725) from The Epidemiology and Natural History ...
Known for Treatment Regimens | Asthma Exacerbations | Impairment Domain | Patients Risk | Baseline Month |
BACKGROUND: The optimal time for transferring responsibilities for anaphylaxis recognition and epinephrine auto-injector use from adults to children and teenagers has not yet been defined.
OBJECTIVE: To determine whether pediatric allergists have age-specific goals for beginning to transfer responsibilities for anaphylaxis recognition and epinephrine auto-injector use from parents and caregivers to children and teenagers at risk of anaphylaxis in the community.
METHODS: Members of the ...
Known for Anaphylaxis Recognition | Children Teenagers | Epinephrine Auto | Transfer Responsibilities | Patients Age |
Key People For Allergic Rhinitis
F Estelle R Simons:Expert Impact
Concepts for whichF Estelle R Simonshas direct influence:Allergic rhinitis, Mosquito allergy, Allergy organization, Atopic dermatitis, Evidence base, Food allergy.
F Estelle R Simons:KOL impact
Concepts related to the work of other authors for whichfor which F Estelle R Simons has influence:Allergic rhinitis, Food allergy, Atopic dermatitis, Chronic urticaria, Severe asthma, Mast cells, Sublingual immunotherapy.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |